OnKure Therapeutics (OKUR) Interest Expenses (2024 - 2025)
OnKure Therapeutics' (OKUR) quarterly Interest Expenses came in at $6000.0 in Q4 2025, down 89.47% on a YoY basis from $57000.0 in Q4 2024, and up 200.0% quarter-over-quarter from $2000.0 in Q3 2025.
Powered by 
Analysis
OnKure Therapeutics (OKUR) Interest Expenses (2024 - 2025) Analysis & Trends
OnKure Therapeutics (OKUR) has reported Interest Expenses for 2 consecutive years, with $6000.0 the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Interest Expenses fell 89.47% year-over-year to $6000.0; the trailing twelve-month figure through Dec 2025 stood at $283000.0 (changed N/A YoY), and the FY2025 full-year result was $8000.0, down 97.33% from the prior year.
- Interest Expenses improved to $6000.0 in Q4 2025 per OKUR's latest filing, from $2000.0 in the prior quarter.
- Across five years, Interest Expenses topped out at $218000.0 in Q3 2024 and bottomed at $2000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | OnKure Therapeutics | 162.57 Mn | -13.81 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 6,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Dec 31, 2024 | 57,000.00 |
| Sep 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 26,000.00 |